Inherited thrombophilia and risk factor interactions in a multigenerational Libyan family with deep vein thrombosis

Abstract :

Deep vein thrombosis (DVT) is a major vascular disorder with significant morbidity and mortality. Inherited thrombophilia defects and acquired risk factors both contribute to its pathogenesis. Familial clustering suggests a strong genetic component, but data from Libyan families are limited. This study aimed to investigate inherited and acquired risk factors for DVT in a multigenerational Libyan family with a history of venous thrombosis. We recruited 10 family members: four symptomatic individuals, three asymptomatic individuals, and three controls. The index case had heterozygous factor V Leiden. We analyzed blood samples collected between October 2024 and January 2025 for fibrinogen, factor V, factor VIII, protein C, protein S, D-dimer, and complete blood count parameters. Body mass index and smoking status were also recorded. Factor V deficiency and elevated factor VIII were each observed in 6/10 participants. Elevated factor VIII was present in all four symptomatic patients. Fibrinogen was elevated in 2/10 participants, both asymptomatic. Protein C deficiency was found in 2/10 participants, and Protein S deficiency in; all were symptomatic. D-dimer was elevated in only one symptomatic patient. Obesity was present in 8/10 participants, and smoking in 3/10, all of whom were symptomatic males. However, between-group comparisons did not reach the significance level. These preliminary findings suggest that inherited thrombophilia factors, particularly factor V deficiency and elevated factor VIII, may contribute to DVT susceptibility in this family, with modifiable risk factors possibly acting as triggers.

References

1. Khan F, Tritschler T, Kahn SR, Rodger MA. Venous thromboembolism. The Lancet. 2021; 398(10294): 64-77. doi: 10.1016/S0140-6736(20)32658-1
2. AL-Belazi BJ, Abuhasina AE, Sherif FM. Thromboembolism in total hip and knee arthroplasty patients receiving low molecular weight heparin prophylaxis. Mediterranean Journal of Medicine and Medical Sciences. 2026; 2(2): 1-12. doi: 10.5281/zenodo.19398969
3. Blanco A, Blanco G. Hemostasis. In: Blanco A, Blanco G, editors. Medical Biochemistry. 1st Ed., San Diego: Academic Press; 2017. ISBN: 9780128035504.
4. Green D. Coagulation cascade. Hemodialysis International. 2006; 10(Suppl 2): S2-S4. doi: 10.1111/j.1542-4758.2006.00119.x
5. Sarrar AM, Rafieda AM, Shaglouf DH, Elshwain WM. Venous and arterial thrombosis during oral contraceptive use in Libyan women. Mediterranean Journal of Medical Research. 2025; 2(4): 259-268. doi: 10.5281/zenodo. 17863440
6. Rosing J, Tans G. Factor V. The International Journal of Biochemistry and Cell Biology. 1997; 29(10): 1123-1126. doi: 10.1016/S1357-2725(97)00040-X
7. Padda IS, Zubair M, Citla Sridhar D. Protein C and S. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan. Updated 2025 Sep 14.
8. Goldenberg RL, Culhane JF, Iams JD, Romero R. Epidemiology and causes of preterm birth. The Lancet. 2008; 371(9606): 75-84. doi: 10.1016/S0140-6736(08)60074-4
9. Alshaikh NA. Protein S: A central regulator of blood coagulation. Clinical Laboratory. 2022; 68(8): 211010. doi: 10.7754/Clin.Lab.2021.211010
10. Korotcenkov G. Factor V Leiden. Dimensions of Critical Care Nursing. 2022; 41(4): 190-199. doi: 10.1002/ ajh.24
11. Pastori D, Menichelli D, Valeriani E, Pignatelli P. Factor V Leiden thrombophilia. In: Adam MP, Bick S, Mirzaa GM, et al., editors. GeneReviews®. Seattle (WA): University of Washington, Seattle; 1999. PMID: 20301542.
12. Lassila R. Management of coagulation factor VIII (FVIII) inhibitors. Thrombosis Research. 2019; 181(Suppl 1): S60-S61. doi: 10.1016/S0049-3848(19)30369-X
13. Kamphuisen PW, Eikenboom JC, Bertina RM. Elevated factor VIII levels and the risk of thrombosis. Arteriosclerosis, Thrombosis, and Vascular Biology. 2001; 21(5): 731-738. doi: 10.1161/01.ATV.21.5.731
14. Wolberg AS, Sang Y. Fibrinogen and factor XIII in venous thrombosis and thrombus stability. Arteriosclerosis, Thrombosis, and Vascular Biology. 2022; 42(8): 931-941. doi: 10.1161/ATVBAHA.122.317164
15. Blokhin IO, Lentz SR. Mechanisms of thrombosis in obesity. Current Opinion in Hematology. 2013; 20(5): 437-444. doi: 10.1097/MOH.0b013e3283634443
16. Rhayem N, Ramah M. Overweight and obesity prevalence in North Africa: A systematic review and meta-analysis. Mediterranean Journal of Medicine and Medical Sciences. 2026; 2(3): 95-105. doi: 10.5281/zenodo.22123267
17. Elmiladi SA GLP-1RA for glycemic control and obesity as add-on therapy for type 2 diabetes. Mediterranean Journal of Pharmacy and Pharmaceutical Sciences. 2023; 3(2): 45-50. doi: 10.5281/zenodo.7942952
18. Nath D, Shivashekar M, Vinodhini VM. Fibrinogen levels in obese and normal individuals. Journal of Clinical and Diagnostic Research. 2019; 13(9): BC07-BC09. doi: 10.7860/JCDR/2019/42041.13162
19. Larsson SC, Mason AM, Bäck M, Klarin D, Damrauer SM, Million Veteran Program, et al. Genetic predisposition to smoking in relation to 14 cardiovascular diseases. European Heart Journal. 2020; 41(35): 3304-3310. doi: 10.1093/eurheartj/ehaa193
20. Zhang T. The related research of hypertension and deep venous thrombosis. China Journal of Modern Medicine. 2010. Corpus ID: 201928315.
21. Bell EJ, Folsom AR, Lutsey PL, Selvin E, Zakai NA, Cushman M, et al. Diabetes mellitus and venous thromboembolism: A systematic review and meta-analysis. Diabetes Research and Clinical Practice. 2016; 111: 10-18. doi: 10.1016/j.diabres.2015.10.019
22. Anderson FA Jr, Spencer FA. Risk factors for venous thromboembolism. Circulation. 2003; 107(23 Suppl 1): I9-I16. doi: 10.1161/01.CIR.0000078469.07362.E6
23. Di Nisio M, van Es N, Büller HR. Deep vein thrombosis and pulmonary embolism. The Lancet. 2016; 388(10063): 3060-3073. doi: 10.1016/S0140-6736(16)30514-1
24. Muñoz Rodríguez FJ. Diagnosis of deep vein thrombosis. Revista Clinica Espanola. 2020: S0014-2565(20)30132-6. doi: 10.1016/j.rce.2020.03.009
25. Neeman E, Liu V, Mishra P, Thai KK, Xu J, Clancy HA, et al. Trends and risk factors for venous thromboembolism among hospitalized medical patients. JAMA Network Open. 2022; 5(11): e2240373. doi: 10.1001/jamanet workopen.2022.40373
26. Kujovich JL. Factor V Leiden thrombophilia. Genetics in Medicine. 2011; 13(1): 1-16. doi: 10.1097/GIM.0b013e 3181faa0f

Citation :

Masoud AM, et al. Inherited thrombophilia and risk factor interactions in a multigenerational Libyan family with deep vein thrombosis. Mediterr J Pharm Pharm Sci. 2026; 6(4): 73-83. [Article number: 272]. https://doi.org/10.5281/zenodo.24005126